A Roundtable Discussion: Combination Products: Twice the Challenge?

Area of Science:

• Regulatory science
• Medical product development
• Manufacturing practices

Background:

• Combination products integrate drugs, devices, and/or biologics.
• FDA established Current Good Manufacturing Practices (CGMP) regulations (21 CFR Part 4) in 2013.
• The Association for the Advancement of Medical Instrumentation (AAMI) developed a technical information report (TIR) to assist with FDA's CGMP regulation implementation.

Purpose of the Study:

• To provide insights into the landscape of combination products.
• To highlight key considerations for developing and obtaining marketing clearance for these products.
• To offer perspectives on current trends in the combination product sector.

Main Methods:

• Discussion with industry and FDA representatives.
• Analysis of AAMI's technical information report (TIR) on CGMP for combination products.
• Exploration of regulatory requirements and best practices.

Main Results:

• The TIR aims to support informed, risk-based decisions for CGMP systems.
• The article explores critical aspects of combination product development and commercialization.
• Insights are provided on navigating the regulatory pathway for innovative combination products.

Conclusions:

• Effective implementation of CGMP is crucial for combination product success.
• Collaboration between industry and regulatory bodies is key to advancing combination product innovation.
• The TIR serves as a valuable resource for manufacturers seeking to comply with FDA regulations.